Development Programs

Antliabio110 - A novel long-acting subcutaneous peptide-based therapy for the treatment of treatment resistant hypertension (rHTN)

• Status - IND enabling

Antliabio 111 - A novel long-acting peptide-based therapy for the treatment of pulmonary arterial hypertension

• Status - Preclinical Development

Antliabio 112 - A novel long-acting peptide-based therapy for the treatment of chronic heart failure (HFpEF and HFrEF)

• Status - Preclinical Development

Antliabio 113 - A novel long-acting peptide-based therapy for the treatment of severe asthma

• Status - Preclinical Development

Antliabio210 - A novel long-acting peptide-based therapy for the treatment of multiple cardiovascular, pulmonary, and metabolic diseases

• Status - Preclinical Development

Antliabio310 - A novel long-acting peptide-based therapy for the treatment of cardiovascular diseases

• Status - Preclinical Development